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Huntington’s disease (HD) is a progressive neurodegenerative disorder that is caused by abnormal expansion of CAG trinucleotide
repeats. Neuroinflammation is a typical feature of most neurodegenerative diseases that leads to an array of pathological changes
within the aﬀected areas in the brain. The neurodegeneration in HD is also caused by aberrant immune response in the presence
of aggregated mutant huntingtin protein. The eﬀects of immune activation in HD nervous system are a relatively unexplored area
of research. This paper summarises immunological features associated with development and progression of HD.
1. Introduction
Huntington’s disease (HD), first discovered by George Hunt-
ington in 1872, is an autosomal-dominant inherited pro-
gressive neurodegenerative disorder that aﬀects control over
movement and cognition along with the development of
psychological symptoms [1]. The prevalence of the clinical
syndrome is 3–7 : 100000 whereas nearly 20 : 100000 are
carriers of the gene responsible for the disease. Symptoms
include weakening of mental abilities leading to a change in
personality (i.e., depression, suicidal tendencies, and in rare
cases, violent behaviour), development of dementia, loss of
psychomotor functions due to lack of muscle coordination,
and abnormal sudden jerky involuntary movements collec-
tively called chorea that heavily aﬀect gait and agility [2].
Although the disease has the potential to present itself at any
time from childhood to old age, it is characterised by the
onset of midlife chorea (around 33–44 years of age) [2].
HD is caused by an abnormal expansion of otherwise
normal CAG trinucleotide polyglutamine repeats (polyQ
repeats) on the N terminus of the IT 15 (Htt) gene, as it
codes for the protein huntingtin (Htt), which was discovered
in 1993 and is located on chromosome 4p16.3 [3]. Htt is
abundantly expressed in the brain and testes with moderate
expression observed in other organs such as liver, heart,
and lungs [2]. Even though the complete function of Htt
still remains unclear, it has been observed to be involved in
cytoskeletal anchoring and transport of mitochondria along
with vesicle traﬃcking to mediate endocytosis, thus im-
plicating in embryogenesis and development [4, 5]. The de-
ficiency of this protein leads to embryonic lethality in HD
knockout mice [6]. Interestingly, Htt has also been shown to
be of importance during the postembryonic stage including
craniofacial development, forebrain formation especially the
cortical and striatal areas and also in survival of neurons
[5, 7]. The active participation of Htt in brain development
and maintenance therefore illustrates the importance of Htt
in the CNS.
In an HD patient, the abnormally amplified CAG repeats
in theHtt gene lead to transcription of themutant huntingtin
(mHtt). The intensity of the disease progression is directly
related to the number of these CAG repeats. For example, in a
normal person, the number of CAG repeats is approximately
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8–39, whereas, in HD, the repeats can range between
36 and 120 in number [8]. This aberrant expansion of
polyglutamine repeats is also implicated in development
of neuronal dysfunction which is consistent with the wild
type Htt function. This dysfunction contributes to the
manifestation of clinical symptoms. Although the mecha-
nism through which mHtt gains toxicity through gain-of-
function still remains under debate, the CAG repeat results in
aggregation of inclusion bodies containing fibrillar mutant
Htt fragments within the striatal neurons. These abnormal
aggregates appear to be the main cause of neurodegeneration
in the disease [9]. During the expression of mHtt, the first
100–150 residues including the polyglutamine repeats are
cleaved oﬀ and these fragments are toxic [10].
The neuropathological hallmark of HD is the degenera-
tion of the nuclei of the basal ganglia situated in the lateral
ventricle brain, that is, the caudate nuclei. The intensity of
the degeneration can vary from mild to severe in the caudate
nuclei while it is less prominent in the putamen. As the
disease progresses, there is a dramatic increase in neuronal
loss from caudate along with presence of both reactive
astrocytes and microglia in the grey matter in the caudate
as opposed to the early stages in which no significant gliosis
is observed [11, 12]. In the neostriatum, mutant Htt is found
in the cell bodies and synaptic processes of surviving neurons
and glial cells. Interestingly, the expression of Htt is not
limited to just the brain but is an ubiquitously expressed
protein [13].
2. Immune System in Brain
The brain was once thought to be an immunologically priv-
ileged organ with an inability to generate humoral and cel-
lular immune responses. The presence of a blood-brain
barrier (BBB) further supported this idea as it separates
the CNS from the rest of the systemic immune system.
However, this case holds true for a healthy CNS that has not
been aﬀected by any immune or inflammatory disorder. In
the event of trauma, axotomy, ischemia, and degeneration,
the immune system within the CNS gets activated. Mi-
croglial cells are resident macrophages of the CNS that are
quiescent in a healthy brain. The activation of microglial
cells leads to upregulation of their cell surface antigens
and secretion of proinflammatory cytokines [14]. This
secretion of cytokines such as IL-6, IL-12, and TNF-α
leads to a dialogue between the neighbouring microglial
cells, astrocytes, T-cells, neurons, and myeloid progenitor
cells. Along with chronic inflammation, the secretion of
these proinflammatory cytokines can lead to free radical
production [15], NMDA-mediated excitotoxicity [16], and
caspase activation [17], causing widespread damage in the
brain due to neuronal death.
3. Immune System in the Huntington’s Disease
Brain: Complement and Cytokines
The presence of a pathological injury within the brain can
initiate an immune response. In most neurodegenerative
diseases, an immune response to the abnormal folding of
proteins and aggregates triggers neuroinflammation which in
turn is implicated in neuronal degeneration. Consistent with
the origin of neuroinflammation and neurodegeneration in
other neurodegenerative diseases [18], mutant Htt aggre-
gates are observed and neostriatal atrophy is a striking feature
in HD brains which suggests massive neurodegeneration in
the neostratum, that is, the putamen and caudate [19]. The
pathogenic protein aggregates are foreign bodies to the oth-
erwise immunoprivileged organ and the antigen presenting
cells of the local immune system, that is, microglial cells are
likely to recognise the aggregates. It is also possible that pro-
tein aggregates cause neuronal death through apoptosis, and
apoptotic bodies can activate microglia and the CNS innate
immune system. The progression of HD still remains poorly
understood. However, premanifest HD, where the carriers
of the gene do not exhibit the classical signs and symptoms
of the typical HD patient, provides important clues to the
disease progression. These include the presence of activated
microglia in the striatum as a result of mHtt aggregation and
early neuronal dysfunction including elevated pathogenic
extrasynaptic NMDA receptor signaling, reduced synaptic
connectivity, and loss of brain-derived neurotrophic factor
(BDNF) [20]. There is also an increase in the expression of
inflammatory cytokines see below.
As mentioned earlier, the resident macrophages of the
brain, microglial cells supervise their microenvironment for
any sign of trauma, injury, or foreign bodies. In the presence
of these stimuli, activation of microglial cells takes place.
Presence of activated microglial cells is a good marker
for immune activation. A recent study reported microglial
activation in presymptomatic HD gene carriers and also an
association between the activation and striatal neuronal dys-
function [12]. This study is supported by an earlier study in
which activated microglia was found throughout the aﬀected
areas in HD and the intensity with which it accumulated
coincided with the grade of disease progression [21]. This
accumulation of microglia leads to a series of events before it
ultimately leads to neuronal loss. However in HD, the precise
mechanism by which the mutant Htt could lead to region-
specific neuronal death is still unclear. A number of studies
have suggested a role of immune components that might
initiate gliosis and neurodegeneration [22–24].
One of the main immune mechanisms involved in the
immune surveillance of the CNS is the complement system
that is activated upon stimulation by pathological peptides
such as mutant Htt. The complement system is a key
factor in several neurodegenerative diseases and is the most
important and powerful humoral component of the innate
immune system [28]. The vital functions of the complement
system include host defence against the action of pathogenic
microorganisms, removal of immune complexes and apop-
totic cells, and facilitate adaptive immune responses [29].
It also mediates the production of anaphylatoxins (C3a,
C4a, and C5a) that trigger degranulation, cell lysis, and
phagocytosis via induction of chemotaxis and cell activation
[29]. Complement system gets activated via three pathways
depending on target ligands and the recognition complement
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Figure 1: The complement system: the classical complement pathway involves a sequentially acting multistep cascade in which the
complement components C1q, C1s, C1r, C4, C2, and C3 play important roles. C1r and C1s, the two serine protease proenzymes, along
with C1q constitute C1, the first component of the classical pathway [25]. The activation of the C1 complex (C1q+C1s–C1r–C1r–C1s)
subsequently activates the complement through the cleavage of C4 and C2 to yield the central molecule C3 convertase that cleaves C3,
leading to the activation of the C2–C9 components and thus the formation of the terminal membrane attack complex (MAC) [26]. The
MAC binds to cell membranes and facilitates cell lysis. The alternative pathway is initiated by low-level activation of C3 via its hydrolysis
(C3b) and activated factor B. The activated C3b binds factor B that is cleaved by factor D to form C3 convertase. The main diﬀerence between
classical and alternative pathway is that the initiation of alternative pathways is not dependent on the presence of immune complexes. The
lectin pathway is activated following the recognition and binding of pathogen-associated molecular patterns (PAMPs) by mannose-binding
lectin (MBL) [27]. The binding of MBL to repetitive carbohydrate patterns on pathogen surfaces has the potential to activate the lectin
pathway through the MBL-associated serine protease (MASP), designated as MASP-2, that in turn leads to the activation of complement
components C4, C2, and C3. The association of MBL-MASP complex of the lectin pathway is analogous to C1 complex of the classical
complement pathway.
component. However, the common aim of all the three path-
ways is to activate the central component of the complement
system, that is, C3 (Figure 1). Altered levels of the activa-
tion of the complement system are considered important
causative factors in inflammatory, neurodegenerative, and
cerebrovascular diseases [28, 30, 31].
Expression of a number of complement components
such as C1q, C1r, C4, C3, as well as the complement regu-
lators, C1 inhibitor, clusterin, MCP, DAF, CD59 in HD brain
samples with severe atrophy, has suggested the recruitment
of the complement system in the HD pathogenesis [23].
Research into the involvement of the peripheral nervous
system in HD is still in its early days. Recently the upreg-
ulation of proinflammatory cytokines such as IL-6, IL-8,
and TNF-α was detected in the peripheral nervous system
HD patients, irrespective of the disease stage [22, 32]. Pro-
teomic profiling of plasma from HD patients also detected
upregulation of proinflammatory cytokines (especially IL-6)
along with other innate immune proteins such as the acute-
phase protein α2-macroglobulin (α2M) and clusterin [32].
Clusterin is a multifunctional glycoprotein that is involved in
diverse mechanisms of cytoprotection, membrane recycling,
and regulation of membrane attack complex. Upregulation
of clusterin is also implicated in a variety of physiological
and pathological states including apoptosis and response
to injury [32]. Clusterin has been previously associated
with other neurodegenerative disorders such as Alzheimer’s
disease (AD) where its plasma level correlates with the degree
of neurodegeneration [33]. Interestingly, clusterin has also
been found to be expressed in both the peripheral plasma
and in CSF thus suggesting widespread immune activation
[32]. Up-regulation of α2M is seen in the peripheral plasma
and its release is stimulated by pro-inflammatory IL-6.
These findings are consistent with observations in AD in
which α2M is upregulated in reactive astrocytes and is also
observed to bind to Aβ which is the pathogenic peptide
responsible for the formation of senile plaques in AD [34].
Thus, a simultaneous upregulation of immune proteins and
cytokines is evident in both the central and peripheral
nervous system in HD.
4 Neurology Research International
4. Neuroinflammation and Neurodegeneration
in HD
Glial cells constitute nearly 90% of the total brain cells, and
their main function is to provide neurons with nutrition,
growth factors, and structural support. These cells are also
responsible for maintaining the normal physiology within
the CNS. The normal brain is devoid of any immune
activation on a day-to-day basis. However, a series of events
and cascades due to infections, trauma, toxins, and stroke
can lead to the pathological neuroinflammation and neuro-
degeneration that are seen in most neurodegenerative dis-
eases, including HD [18, 35]. Neuroinflammation is seen
as a double-edged sword, that is, having both beneficiary
and harmful eﬀects. Acute neuroinflammation is helpful in
elimination of toxins and necrotic cells, and it is the more
beneficiary type of inflammation within the CNS. Microglia
are stimulated by these substances and takes on a phagocytic
role along with the secretion of various cytokines and
chemokines. However, this type of inflammation is a short-
lived phenomenon. Despite the oxidative and nitrosative
stress, the process is seldom harmful to long-term neuronal
survival. Hence, it minimises further damage to the brain
cells along with repairing damaged tissue. On the other hand,
chronic neuroinflammation is associated with exacerbating
neuronal damage. Chronic neuroinflammation includes not
only the extended activation and proliferation of microglia
but also increased secretion of proinflammatory cytokines
and increased superoxide and nitric oxide production.
This prolonged inflammation aﬀects the BBB which in
turn supports the infiltration of macrophages and myeloid
progenitor cells into the brain parenchyma that further
intensifies the already augmented inflammation. Thus, the
detrimental eﬀects of chronic inflammation are highlighted
in neurodegenerative diseases as opposed to the beneficial
acute inflammation (Figure 2).
Under normal conditions, microglial cells are in a qui-
escent state with extremely sensitive spidery processes mon-
itoring the microenvironment around them and lack MHC
class I and II proteins. Upon activation, these cells take up
the role of antigen presenting cells and in turn activate T
cells. Activated microglia play an important role in the devel-
opment and progression of HD as well as other neurode-
generative diseases like AD and Parkinson’s disease [18, 36].
Several studies have examined the association of microglial
activation with progression of HD. A postmortem study
of HD brains revealed significant accumulation between
activated microglia in regions aﬀected by HD, especially the
basal ganglia and the frontal cortex [21]. Interestingly, the
density of activated microglia correlated and the severity of
HD pathology, suggesting a pronounced association between
microglial activation and subsequent neuronal death [21].
Tai et al. were the first to report evidence of activated
microglia in the brains of presymptomatic HD individuals
and striatal neuronal dysfunction [12]. The presence of
reactive microglia was also seen in early manifest HD, the
intensity of which again consistently increased with the
progression of the disease [21]. Positron emission topogra-
phy (PET) imaging studies on presymptomatic, manifest,
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Figure 2: Comparison of immune activation in normal brain
(a) versus HD brain (b). The normal brain is in a state wherein
the microglia cells are in a resting state and are surveying its
microenvironment. The BBB protects the brain from circulating
immune cells such as DCs as well as pathogens and other foreign
material. However, in the HD brain, the damaged neuron has
aggregated mHtt and this activates the resting microglia cells and
hence leads to phagocytosis of the cell debris along with secretion of
proinflammatory cytokines that leads to neuroinflammation. This
neuroinflammation weakens the BBB leading to infiltration of DCs
and further elicits the immune response. Microglia cells that express
mHtt also contribute to the inflammation and degeneration of the
brain cells.
and post mortem brains have positively reported diﬀerent
intensities ofmicroglial activation that correlates with disease
progression; however microglial activation in a minority of
presymptomatic HD brains was undetectable due to the
possibility of the patients being further away from developing
the disease [11, 37].
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Whether inflammation in the CNS is in response to
neuronal death caused by the toxic mutant Htt or vice versa
is debatable. In the aﬀected areas of the brain, the expanded
mutant Htt is found in the form of N-terminal fragments,
oligomers, and polymers (instead of intact monomeric
form), mostly accumulating in the cortex [38]. Mutant Htt
is known to be a key factor in promoting inflammation
in HD, either directly or indirectly. However, the question
now arises if the inflammation is brought about by mutant
Htt expressed in the milieu or by inflammation due to the
activated microglia. The increased expression of the immune
molecules along with the secretion of proinflammatory
cytokines is an abnormal state for an otherwise immuno-
privileged brain, and the widespread inflammation in HD is
evident through the upregulation of cytokines both in the
CNS and the peripheral plasma.
Studies to assess the toxicity of mutant Htt and its asso-
ciation with neurodegeneration and neuroinflammation
have been carried out in recent years. Expression of mutant
Htt in glial cells, including astrocytes andmicroglia, has been
implicated in supporting the inflammation observed in HD.
Mouse models of HD (R6/2 transgenic mice) that exhibit
a HD phenotype have shown expression of mutant Htt
within glial cells, especially in astrocytes. The intranuclear
expression of mutant Htt reduced the neuroprotective func-
tion of astrocytes, rendering neurons vulnerable to degen-
eration [39, 40]. The glial cells are also known to protect
neurons against excitotoxicity by clearing excess excitatory
neurotransmitters from the extracellular space [41]. This
intranuclear expression of mutant Htt has been suggested to
lead to degeneration of the medium sized spiny neurons in
the striatum of the HD brain [39] and also exacerbate the
neurological symptoms [40]. In addition, mutant huntingtin
aggregates within neuronal cells have been identified using
immunofluorescence techniques [38]. Interestingly, the N-
terminal mutant Htt in glial cells promoted the death of
neurons (neurons that did not express mutant Htt) [39].
Neuroinflammation is also caused by the release of cytok-
ines and chemokines from the microglial cells as described
earlier and the subsequent respiratory burst and oxidative
stress. The overall inflammatory response seen in HD may
occur simultaneously in the CNS and in the periphery or
begin peripherally and spread centrally across the BBB or
vice versa, involving immunomodulatory molecules [22].
One such association is of C5a, which activates phagocytes
and local mast cells to release their granules containing his-
tamine and TNF-α. The cytokines secreted by macrophages
include IL-6, IL-1β, IL-12, and TNF-α, and certainly the
upregulation of IL-6 in HD patients has been identified
in the periphery [22]. TNF-α stimulates the migration of
dendritic cells carrying the mutant Htt protein aggregates
from peripheral tissues to lymph nodes and maturation
which would initiate the adaptive immune response which
in turn augment a peripheral immune response [22]. This
infiltration of the immune cells from the peripheral plasma
into the CNS might be due to the weakening of the BBB
preceded by neuroinflammation. A study using RT-PCR
and in situ hybridisation revealed that the classical pathway
components including C1q (C chain), C1r, C4, C3, as well
as the complement regulators are expressed at much higher
level in HD brains compared to normal brain. Complement
activation on neurons and increased biosynthesis of C1q,
the initiation subcomponent of the classical complement
pathway, by microglia [23] suggests the possibility of the
activation of the classical complement pathway contributing
to the neuroinflammation. Whether this complement acti-
vation is due to the mutant Htt aggregation or due to
apoptotic/necrotic neuronal cells is still unclear. In general,
the widespread neuroinflammation contributes to neuronal
death and vice versa, leading to progressive memory and
motor function loss.
5. Perspectives and Conclusion
HD is a progressive age-dependent neuropathological disor-
der in which the immune activation is seen to be predom-
inant in both the CNS and the periphery. The mutant Htt
aggregates appear to trigger neurodegeneration and chronic
neuroinflammation, which correlates well with HD clinical
syndromes. Studies that would identify novel immunological
biomarkers and their levels within the plasma and CNS can
help monitor the progression of the disease. A potential
upregulation of complement in premanifest HD is likely
to be a useful immune biomarker in monitoring disease
progression.
An important role of the process of autophagy has been
shown to be involved in HD. Autophagy is a cell homeostatic
mechanism of intracellular degradation to ensure continu-
ous turnover of the intracellular components. This involves
formation of autophagosomes, the double membrane struc-
tures, which fuse with the primary lysosomes. The contents
of these autophagosomes are degraded in the lysosomes
and either disposed oﬀ or recycled back to the cell [42].
In addition to housekeeping cellular function, autophagy is
also considered important for the degradation of aggregated
proteins. In HD, Htt-containing vacuoles display the ultra-
structural features of early and late autophagosomes. In vitro,
Htt-containing cytoplasmic vacuoles contain the lysosomal
enzyme cathepsin D, thus suggesting the role of autophagy
in HD [43]. The removal of both soluble and aggregate forms
of mutant Htt via autophagy appears to be a neuroprotective
mechanism [44]. However, a recent report of a slower and
ineﬃcient degradation of mutant Htt due to possible defect
in autophagy may be one of the mechanisms of mutant Htt
accumulation and subsequent neuroinflammation in HD
[45, 46]. The contribution of the process of autophagy in the
pathogenesis of HD needs further research. Studies involving
the control of neurodegeneration and neuroinflammation
in the CNS as well as the periphery by decreasing the
upregulation of the inflammatory immune proteins as well
as cytokines would pave way for a better prognosis of patients
aﬀected by HD. This could be made possible by developing
therapeutic agents that target the complement andmicroglial
activation, which in turn, would inhibit the concomitant
release of proinflammatory cytokines.
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